Berit Gravdehaug

• Ohnstad, Hege Oma; Blix, Egil Støre; Akslen, Lars Andreas; Gilje, Bjørnar; Raj, Sunil Xavier & Skjerven, Helle [Vis alle 46 forfattere av denne artikkelen] (2024). Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1). ESMO Open. ISSN 2059-7029. 9(6). doi: 10.1016/j.esmoop.2024.103475.
• Tahri, Naima Borg; Gravdehaug, Berit; Bahrami, Nazli & Reitsma, Laurens Cornelus (2024). En kvinne i 50-årene med postoperativ infeksjon, generalisert utslett og organsvikt. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 144(5). doi: 10.4045/tidsskr.23.0623.
• Mecinaj, Albulena; Gulati, Geeta; Ree, Anne Hansen; Gravdehaug, Berit; Røsjø, Helge Rørvik & Steine, Kjetil [Vis alle 10 forfattere av denne artikkelen] (2024). Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction. JACC: CardioOncology. ISSN 2666-0873. 6(1), s. 83–95. doi: 10.1016/j.jaccao.2023.10.008.
• Strømsvik, Nina; Olsson, Pernilla Marie A.; Gravdehaug, Berit; Lurås, Hilde; Schlichting, Ellen & Jørgensen, Kjersti [Vis alle 11 forfattere av denne artikkelen] (2022). “It was an important part of my treatment”: a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing. Hereditary Cancer in Clinical Practice. ISSN 1731-2302. 20(6). doi: 10.1186/s13053-022-00212-6. Fulltekst i vitenarkiv Vis sammendrag

  Background: In South-Eastern Norway, genetic testing for BRCA1 and BRCA2 is offered to breast cancer patients by their treating surgeon or oncologist. Genetic counselling from a geneticist or a genetic counsellor is offered only to those who test positive for a pathogenic variant or have a family history of cancer. This practice is termed "mainstreamed genetic testing". The aim of this study was to learn about patients' experience of this healthcare service. Methods: Qualitative in-depth interviews were conducted with 22 breast cancer patients who had been diagnosed during the first half of 2016 or 2017 at one regional and one university hospital and who had been offered testing by their treating physician. A six-phase thematic approach was used to analyse the data. Results: The participants had varied experiences of how and when testing was offered. Three main themes emerged from the analysis: 1. informational and communicational needs and challenges during a chaotic time, 2. the value of genetic testing and 3. the importance of standardised routines for mainstreamed genetic testing. Conclusions: Despite the shock of their diagnosis and the varying experiences they had in respect of how and when testing was offered, all of the participants emphasised that genetic testing had been an important part of their diagnosis and treatment. Our results indicate that there is a need for continuous collaboration between geneticists, surgeons, oncologists and laboratory specialists in order to establish simple and robust routines so as to ensure that all eligible breast cancer patients are offered testing at a point when the test result can have an impact on treatment. Keywords: BRCA1, BRCA2; Breast cancer; Genetic testing for breast cancer; Mainstreamed genetic testing; Qualitative study.

• Bahrami, Nazli; Jabeen, Shakila; Tahiri, Andliena; Sauer, Torill; Ødegård, Hilde Presterud & Geisler, Stephanie Beate [Vis alle 11 forfattere av denne artikkelen] (2021). Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin. Breast Cancer Research and Treatment. ISSN 0167-6806. 190, s. 435–449. doi: 10.1007/s10549-021-06399-x. Fulltekst i vitenarkiv
• Heck, Siri Lagethon; Mecinaj, Albulena; Ree, Anne Hansen; Hoffmann, Pavel; Schulz-Menger, Jeanette & Fagerland, Morten [Vis alle 12 forfattere av denne artikkelen] (2021). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): Extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. ISSN 0009-7322. 143(25), s. 2431–2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Fulltekst i vitenarkiv
• Bahrami, Nazli; Chang, Gregory; Kanaya, Noriko; Sauer, Torill; Park, Daehoon & Loeng, Marie [Vis alle 9 forfattere av denne artikkelen] (2020). Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. Journal of Steroid Biochemistry and Molecular Biology. ISSN 0960-0760. 200, s. 1–8. doi: 10.1016/j.jsbmb.2020.105641. Fulltekst i vitenarkiv
• Grindedal, Eli Marie; Jørgensen, Kjersti; Olsson, Pernilla Marie A.; Gravdehaug, Berit; Lurås, Hilde & Schlichting, Ellen [Vis alle 10 forfattere av denne artikkelen] (2020). Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. Familial Cancer. ISSN 1389-9600. 19(2), s. 133–142. doi: 10.1007/s10689-020-00160-x. Fulltekst i vitenarkiv Vis sammendrag

  Studies have shown that a significant number of eligible breast cancer patients are not offered genetic testing or referral to genetic counseling. To increase access to genetic testing in South Eastern Norway, testing has since 2014 been offered directly to breast cancer patients by surgeons and oncologists. This practice is termed "mainstreamed genetic testing". The aim of this study was to investigate to what extent patients in South Eastern Norway are offered testing. Three hundred and sixty one patients diagnosed in 2016 and 2017 at one regional and one university hospital in South Eastern Norway were included. Data on whether the patients fulfilled the criteria, whether they had been offered testing and if they were tested were collected. In total, 26.6% (96/361) fulfilled the criteria for testing. Seventy five percent (69/92) of these were offered testing, and 71.7% (66/92) were tested. At the university hospital, 90.2% (37/41) of eligible patients were offered testing, and at the regional hospital 62.7% (32/51). Fifty two percent (12/23) of eligible patient not offered testing were younger than 50 years at time of diagnosis. As many as 95.4% (125/131) of all patients who were offered testing, wanted to be tested. The majority of patients who fulfilled the criteria were offered testing, supporting the practice of mainstreamed genetic testing. There were nevertheless differences in rates of testing between the hospitals that affected all groups of patients, indicating that genetic testing may not be equally accessible to all patients. We suggest that efforts should be made to increase awareness and improve routines for genetic testing of breast cancer patients in Norway. Keywords: BRCA; Breast cancer; Genetic testing; Mainstreaming cancer genetics.

• Bahrami, Nazli; Sauer, Torill; Engebretsen, Siri Strøm; Aljabri, Mohammad Belal; Bemanian, Vahid & Lindstrøm, Jonas Christoffer [Vis alle 17 forfattere av denne artikkelen] (2019). The NEOLETEXE trial: a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors. Future Oncology. ISSN 1479-6694. 15(32), s. 3675–3682. doi: 10.2217/fon-2019-0258. Fulltekst i vitenarkiv
• Sauer, Torill; Doughty, Richard W.; Orzsagh, Vivian & Gravdehaug, Berit (2018). The Cytopathologist in the Hospital - Based Fnac Clinic: US Image Guidance is Our New Tool to an Even Better Fnac Practice. Mathews Journal of Cytology and Histology. ISSN 2577-4158. 2(1). Fulltekst i vitenarkiv
• Heck, Siri Lagethon; Gulati, Geeta; HOFFMANN, PAVEL; von Knobelsdorff-Brenkenhoff, Florian; Storås, Tryggve & Ree, Anne Hansen [Vis alle 12 forfattere av denne artikkelen] (2018). Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: The PRADA trial. European Heart Journal-Cardiovascular Imaging. ISSN 2047-2404. 19(5), s. 544–552. doi: 10.1093/ehjci/jex159. Fulltekst i vitenarkiv Vis sammendrag

  Aims: Anthracycline treatment may cause myocyte loss and expansion of the myocardial extracellular volume (ECV) fraction by oedema and fibrosis. We tested the hypotheses that adjuvant treatment for early breast cancer with the anthracycline epirubicin is dose dependently associated with increased ECV fraction and total ECV, as well as reduced total myocardial cellular volume, and that these changes could be prevented by concomitant angiotensin or beta-adrenergic blockade. Methods and results: PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA) was a 2 × 2 factorial, placebo-controlled, double-blinded trial of candesartan and metoprolol. Sixty-nine women had valid ECV measurements. ECV fraction, total ECV, and total cellular volume were measured by cardiovascular magnetic resonance before and at the completion of anthracycline therapy. ECV fraction increased from 27.5 ± 2.7% to 28.6 ± 2.9% (P = 0.002). A cumulative doxorubicin equivalent dose of 268 mg/m2 was associated with greater increase in ECV fraction than doses <268 mg/m2 (mean change 3.4% [95% confidence interval (CI) 1.2, 5.5] vs. 0.7% [95% CI 0.0, 1.5], P = 0.006), as well as greater increase in total ECV (1.9 mL [95% CI 0.4, 3.5] vs. 0.1 mL [95% CI -0.6, 0.8], P = 0.04). In patients receiving candesartan, total cellular volume decreased (-3.5 mL [95% CI - 4.7, -2.2], P < 0.001) while in patients not receiving candesartan, it remained unchanged (P = 0.45; between group difference P = 0.003). Conclusions: Anthracycline therapy is associated with dose-dependent increase in ECV fraction and total ECV. Concomitant treatment with candesartan reduces left ventricular total cellular volume.

• Gulati, Geeta; Heck, Siri Lagethon; Røsjø, Helge; Ree, Anne Hansen; HOFFMANN, PAVEL & Hagve, Tor-Arne [Vis alle 11 forfattere av denne artikkelen] (2017). Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: Results from the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) study. Journal of the American Heart Association (JAHA). ISSN 2047-9980. 6(11). doi: 10.1161/JAHA.117.006513. Fulltekst i vitenarkiv
• Gulati, Geeta; Heck, Siri Lagethon; Ree, Anne Hansen; HOFFMANN, PAVEL; Schulz-Menger, Jeanette & Fagerland, Morten [Vis alle 15 forfattere av denne artikkelen] (2016). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. European Heart Journal. ISSN 0195-668X. 37(21), s. 1671–1680. doi: 10.1093/eurheartj/ehw022.
• Gulati, Geeta; Heck, Siri Lagethon; Ree, Anne Hansen; Gravdehaug, Berit; Røsjø, Helge & Steine, Kjetil [Vis alle 10 forfattere av denne artikkelen] (2013). Cardioprotective treatment during adjuvant cancer therapy. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 133(17), s. 1832–1836. doi: 10.4045/tidsskr.12.1514.
• Heck, Siri Lagethon; Gulati, Geeta; Ree, Anne Hansen; Schulz-Menger, Jeanette; Gravdehaug, Berit & Røsjø, Helge [Vis alle 11 forfattere av denne artikkelen] (2012). Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial. Cardiology. ISSN 0008-6312. 123(4), s. 240–247. doi: 10.1159/000343622.

Se alle arbeider i Cristin

• Strømsvik, Nina; Olsson, Pernilla Marie A.; Gravdehaug, Berit; Mæhle, Lovise; Schlichting, Ellen & Lurås, Hilde [Vis alle 11 forfattere av denne artikkelen] (2021). Eighth International Symposium on hereditary breast and ovarian cancer. Familial Cancer. Familial Cancer. ISSN 1389-9600. doi: 10.1007/s10689-021-00273-x.
• Strømsvik, Nina; Olsson, Pernilla Marie A.; Gravdehaug, Berit; Mæhle, Lovise Olaug; Lurås, Hilde & Schlichting, Ellen [Vis alle 11 forfattere av denne artikkelen] (2021). Breast Cancer Patients' Experiences with Mainstreamed Genetic Testing in Two Hospitals in South Eastern Norway - Preliminary results. Vis sammendrag

  Background: In South Eastern Norway, genetic testing of BRCA1 and BRCA2 is mainstreamed into regular oncological care. Testing is offered directly to breast cancer (BC) patients by surgeons and oncologists. Only patients who test positive for a pathogenic BRCA variant or have a family history of cancer, are referred to genetic counseling. The aim of this study was to gain knowledge on how BC patients experience this health care service. Methods: Thirty women, diagnosed with BC during the first half of 2016 or 2017 at one regional and one university hospital, and who had been tested by their treating physician were invited.. Twenty two (73%) consented to inclusion, and qualitative individual interviews were undertaken with all of them. The data were analysed using a thematic approach. Results: Being diagnosed with BC was a shock that created a need for and an obstacle to absorbing and remembering information. A feeling of trust in the health care providers facilitated communication in this chaotic period. The women regarded genetic testing as important for themselves, their cancer treatment and their relatives. The participants’ experience of how genetic testing was offered, the amount of information they received and how they had received the test result varied. Not all patients had been offered testing, and some had asked for the test themselves. The participants emphasized the importance of having routines to secure that all eligible patients were given the opportunity of being tested. Conclusions: Based on the findings in this qualitative study of BC patients’ experience with mainstreamed genetic testing, we conclude that access to testing during diagnosis and treatment had been important to these women. Their varied experiences regarding when and how they had been offered testing indicate that there may be a need to strengthen and unify routines for this health care service.

• Vaske, Charlie; Parulkar, R.; Bahrami, Nazli; Sauer, Torill; Lüders, Torben & Lorentzen, Annika [Vis alle 9 forfattere av denne artikkelen] (2019). Time-course DNA and RNA profiling reveals down-regulation of all members of the sulfotransferase 1A subfamily during neoadjuvant therapy with aromatase inhibitors.
• Vaske, Charlie; Bahrami, Nazli; Parulkar, R.; Newton, Y.; Sauer, Torill & Loeng, Marie [Vis alle 11 forfattere av denne artikkelen] (2018). Time-course DNA and RNA profiling of tumors from intra-patient cross-over trial of sequential use of aromatase inhibitors.
• Bahrami, Nazli; Chang, G.; Kanaya, N.; Sauer, Torill; Loeng, Marie & Gravdehaug, Berit [Vis alle 8 forfattere av denne artikkelen] (2018). Total estrogenic activity during neoadjuvant therapy with letrozole and exemestane: An intra-patient cross-over comparison using the AroEr tri-screen.
• Bahrami, Nazli; Sauer, Torill; Loeng, Marie; Gravdehaug, Berit; Engebretsen, Siri & Aljabri, Belal [Vis alle 11 forfattere av denne artikkelen] (2018). The NEO-LET-EXE trial: an intra-patient cross-over study to explore the lack of cross-resistance between steroidal and nonsteroidal aromatase inhibitors .
• Heck, Siri Lagethon; Gulati, Geeta; HOFFMANN, PAVEL; von Knobelsdorff-Brenkenhoff, Florian; Storås, Tryggve & Ree, Anne Hansen [Vis alle 11 forfattere av denne artikkelen] (2016). Effects of Candesartan and Metoprolol on Myocardial Mass, Edema, and Fibrosis During Anthracycline Treatment in Early Breast Cancer: APRADA-CMR substudy.
• Sauer, Torill; Orszagh, Vivian C; Doughty, Richard W.; Dahl, Sverre; Gravdehaug, Berit & Chen, Ying (2016). An audit of a pathologist performed US-guided FNAC out patient clinic; the Ahus institutional experience.
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Gravdehaug, Berit; Ree, Anne Hansen & HOFFMANN, PAVEL [Vis alle 9 forfattere av denne artikkelen] (2016). Atrio-ventricular plane excursion is impaired after ten weeks of anthracycline treatment in breast cancer patients; Data from the PRADA-study.
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Gravdehaug, Berit; HOFFMANN, PAVEL & Steine, Kjetil [Vis alle 9 forfattere av denne artikkelen] (2016). Troponin I and Cardiac Function During Breast Cancer Therapy in Human Epidermal Growth Factor Receptor 2 Positive and Negative Patients: Results from the PRADA Study.
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Fagerland, Morten; HOFFMANN, PAVEL & Gravdehaug, Berit [Vis alle 10 forfattere av denne artikkelen] (2016). Effect of candesartan and metoprolol on subclinical myocardial injury during anthracycline therapy: data from the prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA) study.
• Gulati, Geeta; Heck, Siri Lagethon; HOFFMANN, PAVEL; Ree, Anne Hansen; Schulz-Menger, Jeanette & von Knobelsdorff-Brenkenhoff, Florian [Vis alle 12 forfattere av denne artikkelen] (2016). Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Primary Results of a Randomized, 2 x 2 Factorial, Placebo-Controlled, Double-Blind Clinical Trial. Circulation. ISSN 0009-7322.
• Gulati, Geeta; Heck, Siri Lagethon; Ree, Anne Hansen; Bratland, Åse; Steine, Kjetil & Schulz-Menger, Jeanette [Vis alle 11 forfattere av denne artikkelen] (2015). Abstract CT321: Prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA study. Cancer Research. ISSN 0008-5472.

Se alle arbeider i Cristin